AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From US Newswire)
To: National Desk, Health Reporter
Contact: Niles Frantz of the Alzheimer's Association, 312-286-0295 (cell) or niles.frantz@alz.org, Alzheimer's Association Media Line: 312-335-4078 or media@alz.org, International Conference on Alzheimer's Disease and Related Disorders press room, July 18-22: 215-418-2054
PHILADELPHIA, July 18 /U.S. Newswire/ -- Individuals with mild cognitive impairment (MCI) who took the Alzheimer drug donepezil had a reduced risk of progressing to Alzheimer's disease compared to those who took placebo, according to preliminary data reported today at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD), presented by the Alzheimer's Association.
The risk reduction appeared to be temporary, lasting for only the first 18 months of a three-year trial. When individuals in the study did progress to Alzheimer's, those taking donepezil developed the disorder an average of six months later than those taking the placebo.
"This is the first study to demonstrate a positive treatment effect on progression to Alzheimer's disease from MCI," said Ronald Petersen, M.D., Ph.D., a principal investigator in the study, which was funded by the National Institute on Aging (NIA). "It looks like the drug had a modest, time-limited effect.…